Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects

Diabetes Care

Volumn 20, Issue 10, 1997, Pages 1598-1602

  Grosskopf, Itamar ^a   Ringel, Yehuda ^a   Charach, Gideon ^a   Maharshak, Nitsan ^a   Mor, Ronit ^a   Iaina, Adrian ^a   Weintraub, Moshe ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHYLOMICRON; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RETINOL PALMITATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE INTOLERANCE; HUMAN; LIPOPROTEIN METABOLISM; LOADING TEST; MALE; OBESITY;

EID: 0030875349     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.10.1598     Document Type: Article

References (34)

1. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 75:809-817, 1985
2. Stout RW: The relationship of abnormal circulatory insulin to atherosclerosis. Atherosclerosis 27:1-13, 1977
3. Nikkilae EA, Miettinen TA: Plasma insulin in coronary artery disease. Lancet ii:508-511, 1965
4. Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131-141, 1979
5. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:154-160, 1979
6. Orchard TJ, Becker DJ: Plasma insulin and lipoprotein concentrations: an atherogenic association. Am J Epidemiol 118:326-327, 1983
7. Zavaroni I, Dallaglio E: Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglycerides. Atherosclerosis 55:250-266, 1985
8. Laakso M, Sarlund H: Insulin resistance in association with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Atherosclerosis 10:223-231, 1990
9. Stout RW: Overview of the association between insulin and atherosclerosis. Metabolism 34:7-12, 1985
10. Denton RM, Brownsey RW: Partial view of the mechanism of insulin action. Diabetologia 21:347-361, 1981
11. Gin H, Messerschmidt C: Metformin improved insulin resistance in type I insulin dependent diabetic patients. Metabolism 34:923-925, 1985
12. Nosadini R, Avogaro A: Effects of metformin on insulin stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 10:62-67, 1987
13. Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation 60:473-485, 1979
14. Ginsberg HN: Lipoprotein metabolism and its relation to atherosclerosis. Med Clin North Am 78:1-17, 1994
15. Redgrave TG: Postprandial remnants and their relation to atherosclerosis. In Latent Dyslipoproteinemias and Atherosclerosis. DeGennes JL, Polonovski J, Paoletti R, Eds. New York, Raven Press, 1984, p. 9-15
16. Weintraub MS, Eisenberg S, Breslow JL: Different patterns of postprandial metabolism in normals and type IIa, type III and type IV hyperlipoproteinemics: Effect of treatment with cholestyramine and gemfibrozil. J Clin Invest 79:1110-1119, 1987
17. Jeppsen J, Zhou MY, Chen Y-DI, Reaven GM: Effect of metformin on postprandial lipidemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 17:1093-1099, 1994
18. Rassin T, Liron M, Rubinstein A, Arad J, Weintraub M: Vitamin A loading: an indicator of post-prandial lipoprotein clearance in healthy and hypertriglyceridemic subjects. Isr J Med Sci 28:706-710, 1992
19. Grundy SM, Mok HYI: Chylomicron clearance in normal and hyperlipidemic man. Metabolism 25:1225-1239, 1976
20. Dale VP, Hamlin JI: Particulate fat in lymph and blood. Physiol Rev 42:674-701, 1962
21. Lindgren FT, Jensen LC, Hatch FT: The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. Nelson GS, Ed. New York, Wiley Interscience, 1972, p. 181-274
22. Blomhoff R, Rasmussen M, Nelsen A, Norum KR, Berg T, Blaner, Kato M, Mertz JR, Mertz DS, Goodman DS, Erickson U, Peterson A: Hepatic retinal metabolism. J Biol Chem 260:13560-13565, 1985
23. Cortner JA, Coates PM, Le NA, Cryer DR, Ragni MC, Falkner A, Langer T: Kinetics of chylomicron remnant clearance in normal and hyperlipoproteinemic subjects. J Lipid Res 28:195-206, 1987
24. DeRuyter MG, De-Leenheer AP: Simultaneous determination of retinol and retinyl esters in serum or plasma by reversed-phase high performance liquid chromatography. Clin Chem 24:1920-1923, 1978
25. Berr F, Eckel RH, Kern F: Plasma decay of chylomicron remnants is not affected by heparin-stimulated plasma lipolytic activity in normal fasting man. J Lipid Res 26:852-859, 1985
26. Bianchi R, Erkelens DW: Role of insulin resistance in human disease. Diabetes Nutr Metab 7:43-51,1994
27. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA: Quantitative study of insulin secretion and clearance in normal obese subjects. J Clin Invest 81:435-441, 1988
28. Polonsky K, Sturis J, Bell G: Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334:777-783, 1996
29. Wu MS, Johnston P, Sheu WH H, Hollenbeck CB, Jeng CY, Chen Y-DI, Reaven GM: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13:1-8, 1990
30. Hollenbeck CB, Johnston P, Varasteh BB, Chen Y-DI, Reaven GM: Effects of metformin on insulin and lipid metabolism in patients with mild hypertriglyceridemia and non-insulin-dependent diabetes by glucose tolerance criteria. Diabete Metab 17:483-489,1991
31. Reavan GM, Johnston P, Hollenbeck CB, Skowronski R, Zhang JC, Goldfine ID, Chen Y-DI: Combined metformin-sulfonylurea treatment of patients with non-insulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 74:1020-1026, 1992
32. Ginsberg HN: Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 14: 839-855, 1991
33. Nosadini R, Avogaro A, Trevisan R, Valerio A, Tessari P, Duner E, Tiengo A, Velussi M, Del Prato S, De Kreutzenberg S, Muggeo M, Crepaldi G: Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 10:62-67, 1987
34. Giuliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387-1390, 1993